Febuxostat, a novel xanthine oxidoreductase inhibitor, improves hypertension and endothelial dysfunction in spontaneously hypertensive rats

Takashi Shirakura1 · Johji Nomura1 · Chieko Matsui1 · Tsunefumi Kobayashi1 · Mizuho Tamura1 · Hiroaki Masuzaki2

Received: 11 February 2016 / Accepted: 28 March 2016 / Published online: 20 May 2016 © The Author(s) 2016. This article is published with open access at SpringerLink.com

Abstract Xanthine oxidase (XO) is an enzyme responsible for the production of uric acid. XO produces considerable amount of oxidative stress throughout the body. To date, however, its pathophysiologic role in hypertension and endothelial dysfunction still remains controversial. To explore the possible involvement of XO-derived oxidative stress in the pathophysiology of vascular dysfunction, by use of a selective XO inhibitor, febuxostat, we investigated the impact of pharmacological inhibition of XO on hypertension and vascular endothelial dysfunction in spontaneously hypertensive rats (SHRs). Sixteen-week-old SHR and normotensive Wistar-Kyoto (WKY) rats were treated with tap water (control) or water containing febuxostat (3 mg/kg/day) for 6 weeks. Systolic blood pressure (SBP) in febuxostat-treated SHR (220 ± 3 mmHg) was significantly (P < 0.05) decreased compared with the control SHR (236 ± 4 mmHg) while SBP in febuxostat-treated WKY was constant. Acetylcholine-induced endothelium-dependent relaxation in aortas from febuxostat-treated SHR was significantly (P < 0.05) improved compared with the control SHR, whereas relaxation in response to sodium nitroprusside was not changed. Vascular XO activity and tissue nitrotyrosine level, a representative indicator of local oxidative stress, were considerably elevated in the control SHR compared with the control WKY, and this increment was abolished by febuxostat. Our results suggest that exaggerated XO activity and resultant increase in oxidative stress in this experimental model contribute to the hypertension and endothelial dysfunction, thereby supporting a notion that pharmacological inhibition of XO is valuable not only for hyperuricemia but also for treating hypertension and related endothelial dysfunction in human clinics.

Keywords Xanthine oxidase · Febuxostat · Endothelial dysfunction · Hypertension

Abbreviations

ACh Acetylcholine
NAD Nicotinamide adenine dinucleotide
NO Nitric oxide
ROS Reactive oxygen species
SBP Systolic blood pressure
SHR Spontaneously hypertensive rat
SNP Sodium nitroprusside
WKY Wistar-Kyoto
XDH Xanthine dehydrogenase
XO Xanthine oxidase
XOR Xanthine oxidoreductase

Introduction

Xanthine oxidoreductase (XOR) catalyzes the oxidation of hypoxanthine to xanthine and on to uric acid, which are the final reactions of purine catabolism in humans. Under physiologic conditions, the enzyme functions mainly as a dehydrogenase (XDH) and uses NAD+ as the electron acceptor. Noticeably, under a variety of pathologic conditions such as
tissue ischemia and tissue damage (Harrison 2002), it can be converted into an oxidase (xanthine oxidase (XO)) using molecular oxygen as the electron acceptor.

Because of its ability to generate reactive oxygen species (ROS), the role of XOR has long been investigated in a wide variety of ROS-related diseases (Boueziz et al. 2008).

Hypertension is a major risk for cardiovascular diseases. A large body of evidence suggests that locally exaggerated oxidative stress is profoundly involved in the pathophysiology of hypertension (Nickenig and Harrison 2002; Ceriello 2008; Cutler et al. 2008; Grossman 2008). In accordance with this notion, augmented oxidative stress has been implicated in vascular dysfunction of several models of experimental hypertension (Fukui et al. 1997; Kerr et al. 1999; Tanito et al. 2004; Touyz 2004). In particular, endothelial dysfunction is a hallmark of hypertension (Locke et al. 1986; Morawietz et al. 2001; Landmesser et al. 2003), which is also evoked by oxidative stress. As one of underlying mechanisms, it is suggested that oxidative stress reduces bioavailability and bioactivity of nitric oxide (NO), a potent endothelium-derived relaxing factor (Li et al. 2013).

Based on the notion that XO produces ROS, it is reasonable to speculate that XO would ameliorate hypertension and associated endothelial dysfunction. However, conflicting results have been reported depending on the experimental hypertensive models (Tian et al. 2005; Zhang et al. 2005; Yamamoto et al. 2006; Ong et al. 2007; Vieil et al. 2008). It also should be noted that most of previous studies used allopurinol to attain the pharmacological XO inhibition. Importantly, allopurinol is a classic suicide inhibitor, as its binding to and reduction of the Mo cofactor induce self-oxidation to form oxypurinol, an active inhibitory metabolite. Reduction of the Mo cofactor by allopurinol leads to ROS production (Galbusera et al. 2006). On the other hand, allopurinol is known to exert radical scavenging effect due to its chemical structure (Augustin et al. 1994). For these reasons, it seems to be hard to precisely evaluate the pharmacological effect of XO inhibition by allopurinol. In contrast, febuxostat is a novel, selective, and potent XO inhibitor with non-purine structure for treating gout in human clinics. Unlike allopurinol, febuxostat does not produce or scavenge ROS by its chemical structure, because it is neither a suicide XO inhibitor nor a radical scavenger (Okamoto et al. 2003). In this sense, febuxostat would be better tool to resolve the issue whether pharmacological XO inhibition reduces blood pressure and improves the endothelial dysfunction in experimental models. To explore the possible involvement of XO-derived oxidative stress in the pathophysiology of vascular dysfunction, we evaluated the impact of febuxostat on hypertension and vascular endothelial dysfunction in spontaneously hypertensive rats (SHRs), representative animal model of human essential or primary hypertension (Zicha and Kunes 1999).

Materials and methods

Animals and treatments

Male SHRs and age-matched Wistar-Kyoto (WKY) rats weighing 200–300 g were purchased from Charles River Japan (Yokohama, Japan) and were maintained under standard conditions until the experiments were done. All studies were performed in accordance with procedures approved by the Animal Ethics Committee of the Teijin Institute for Biomedical Research Institute, Teijin Pharma Limited, Tokyo, Japan.

Four groups of rats were used in this study: (1) WKY control rats (WKY-C), (2) febuxostat-treated WKY rats (WKY-Fx), (3) control SHR (SHR-C), and (4) febuxostat-treated SHR (SHR-Fx). WKY-C and SHR-C groups were given tap water. The WKY-Fx and SHR-Fx groups were given febuxostat dissolved in drinking water ad libitum at a concentration of 0.03 mg/L. At this concentration, the dose of febuxostat per day calculated by the daily water intake and body weight was approximately 3 mg/kg/day. As a matter of fact, we recently found that single oral administration of febuxostat at 1, 3, and 10 mg/kg to rats showed dose-dependent inhibition of XO activity in plasma and aorta (data not shown). It should be noted that repeated administration of XO inhibitor at high dose in rodents results in death, partly because xanthine calculi caused renal impairment due to inhibition of XOD/XDH (Isa et al. 1968). According to this notion, oral administration of febuxostat at 10 mg/kg for 28 days caused calculi in 1 of 30 animals (Horiuchi et al. 1999). In this context, to achieve the maximal inhibition of XO and avoid possible renal damages, we carefully selected 3 mg/kg/day as a dose of febuxostat. The febuxostat treatment was started at 16 weeks of age and carried out for 6 weeks. Systolic blood pressures (SBPs) were measured before and 2, 4, and 6 weeks during the drug treatment. Vascular function, XO activity, and other biochemical parameters were determined at 6 weeks.

Blood pressure measurement

SBP was measured using a tail-cuff sphygmomanometer (Visitech BP2000, Visitech Systems, Apex, NC). All animals were acclimated for blood pressure measurements 1 week before drug treatment.

Xanthine oxidase activity

Plasma and tissue XO activities were measured by the pterin-based assay. In brief, frozen tissues were homogenized with potassium phosphate buffer, pH 7.4, containing 1 mM ethylenediaminetetraacetic acid (EDTA) and protease inhibitors. The homogenates were centrifuged 12,000 rpm for 15 min at 4 °C, and supernatants were co-incubated with 50-μM...
pterin solution to assay XO activity. After 60-min incubation at 37 °C, fluorometric assays were performed to calculate the production of isoxanthopterin. Activity of purified XO derived from buttermilk (Calbiochem) and protein concentration were measured and used to normalize the sample activity.

In vitro organ bath studies

The animals were sacrificed at the end of the 6-week study by decapitation under pentobarbital anesthesia. The thoracic aorta was isolated carefully and cut into 3-mm-length ring. The ring segments were mounted in organ baths containing 5 mL of Krebs-Henseleit solution aerated with 95 % O2 and 5 % CO2 and warmed at 37 °C. The composition of Krebs-Henseleit solution is as follows (mM): NaCl (119), KCl (4.7), CaCl2 (2.5), MgSO4 (1.2), NaHCO3 (25), KH2PO4 (1.2), and glucose (10); pH7.4. Each ring was connected to a force transducer (FD, NIHON KODEN, Tokyo, Japan) for isometric force recording. The rings were stretched to 2 g of optimal tension and equilibrated for 60 min until a stable baseline tone was obtained.

Following equilibration, the rings were repeatedly exposed to 60 mM KCl, and then, the presence of endothelium was verified by the ability of acetylcholine (ACh, 1 × 10–6 M) to relax phenylephrine (PE, 1 × 10–7 M)-induced contraction. After washout, endothelium-mediated relaxation was measured as a concentration-response curve to ACh (1 × 10–10 – 1 × 10–4 M) in rings contracted with the submaximal dose of PE (5 × 10–7 M). Endothelium-independent relaxation was also measured as a concentration-response curve to sodium nitroprusside (SNP) (1 × 10–10–1 × 10–4 M).

Oxidative stress measurement

Tissues were weighed and homogenized with 0.05 M potassium phosphate buffer, pH 7.4, containing 1 mM EDTA and protease inhibitors. Homogenates were centrifuged at 12,000 rpm for 15 min at 4 °C, and the supernatants were collected and used for assay. The measurement of nitrotyrosine was performed by using a commercially available nitrotyrosine assay kit (Northwest Life Science, CA, USA) according to the manufacturer’s instructions.

Plasma uric acid level

Plasma uric acid levels were determined by an enzymatic method based on the uricase-peroxidase system (PUREAUTO® S CRE-N, Sekisui Medical Co. Ltd., Japan).

Statistical analysis

Data are expressed as mean ± SEM. The responses to ACh and SNP are expressed as percentages of PE contraction. Statistical calculations for significant differences were performed by using Student’s t test. Significance was accepted at P<0.05.

Results

General conditions of animals

Febuxostat treatment did not alter the body weight in both WKY rats and SHRs. The plasma uric acid levels were similar in WKY-C and SHR-C groups (Table 1). Febuxostat treatment significantly decreased plasma uric acid levels in both WKY rats and SHRs to the same extent (0.9±0.1 mg/dL in WKY-C, 0.5±0.1 mg/dL in WKY-Fx, 1.0±0.1 mg/dL in SHR-C, and 0.5±0.1 mg/dL in SHR-Fx; Table 1).

Systolic blood pressure

SBP in the SHR-C group was significantly higher compared to that in the WKY-C group. Febuxostat treatment significantly (P<0.05) decreased SBP in the SHRs (236 ± 4 mmHg in SHR-C, 220 ± 3 mmHg in SHR-Fx, Fig. 1), while it did not alter SBP in the WKY rats after 6-week treatment (164 ± 7 mmHg in WKY-C, 156 ± 9 mmHg in WKY-Fx, Fig. 1).

Vascular and plasma xanthine oxidase activity

XO activity in the thoracic aorta of SHRs was significantly higher than that of WKY rats (Fig. 2a). The treatment with febuxostat lowered this activity in both strains (957 ± 214 μU/mg protein in WKY-C, 463 ± 114 μU/mg protein in WKY-Fx, 2549 ± 427 μU/mg protein in SHR-C, and 805 ± 73 μU/mg protein in SHR-Fx, Fig. 2a). Similarly, the level of XO activity in plasma of SHRs was significantly higher than that of WKY rats (Fig. 2b). Treatment with febuxostat reduced this activity in both strains (80.5 ± 2.2 mU/mL in WKY-C, 19.0 ± 2.5 mU/mL in WKY-Fx, 113.4 ± 6.4 mU/mL in SHR-C, and 31.7 ± 2.1 mU/mL in SHR-Fx, Fig. 2b).

Vascular oxidative stress

To investigate the therapeutic effect of febuxostat on oxidative stress, we examined the tissue nitrotyrosine level. Nitrotyrosine, a marker of nitro-oxidative stress in the thoracic aorta of SHRs, was significantly higher than that of WKY rats (Fig. 3). The treatment with febuxostat lowered nitrotyrosine concentration in both strains (Fig. 3).

Vascular reactivity

Finally, we evaluated the effect of febuxostat on endothelial function. ACh-induced endothelium-dependent relaxation in
the thoracic aorta was attenuated in SHR compared to that of WKY rats (P < 0.01, Fig. 4a). Febuxostat treatment restored the endothelium-dependent relaxation in comparison to the untreated SHRs (P < 0.05, Fig. 4a). The endothelium-independent relaxation measured using SNP, a direct NO donor, was similar in SHRs and WKY rats (Fig. 4b). Febuxostat treatment did not alter the relaxation in response to SNP in both WKY rats and SHRs.

Discussion

By using a novel, selective xanthine oxidase inhibitor febuxostat, the present study aimed to investigate the therapeutic effects of pharmacological inhibition of XO on hypertension and endothelial dysfunction in SHRs. Our data demonstrated that the therapeutic dose of febuxostat appropriate for hyperuricemia considerably decreased the SBP, reduced the vascular and plasma XO activity, suppressed the vascular nitrotyrosine level, and improved endothelial dysfunction in SHR.

Mechanism of action of XO inhibition

In the present study, XO activities in both aorta and plasma from SHRs were significantly elevated as compared to that of WKY rats. Importantly, treatment of febuxostat substantially lowered aorta and plasma XO activities in both strains. Circulating XO binds to glycosaminoglycan residues on the surface of endothelium in a partially heparin-reversible manner and subsequently translocates to intracellular compartments (Radi et al. 1997; Houston et al. 1999). Although mechanisms whereby plasma XO activity is elevated in SHRs are not yet entirely clarified, it has been reported that XO is released from several organs into systemic circulation in a line of pathophysiology including hepatitis, hemorrhagic shock, sickle cell disease, and ischemia reperfusion (Yokoyama et al. 1990; Tan et al. 1998; Aslan et al. 2001). SHRs represent a variety of organ damages related to severe hypertension (Liu et al. 2011; Boon

### Table 1 Body weight and plasma uric acid

|                  | WKY-C | WKY-Fx | SHR-C | SHR-Fx |
|------------------|-------|--------|-------|--------|
| BW (g)           | 376 ± 5 | 370 ± 6 | 384 ± 4 | 387 ± 4 |
| Uric acid (mg/dL)| 0.9 ± 0.1 | 0.5 ± 0.1** | 1.0 ± 0.1NS | 0.5 ± 0.1## |

Values are means ± SEM (n = 9–10 per group)  
NS not significant WKY-C vs SHR-C, Student’s t test  
**P < 0.01 WKY-C vs WKY-Fx, ##P < 0.01 SHR-C vs SHR-Fx

**Improvement in hypertension and endothelial dysfunction**

Our results showed that the therapeutic dose of febuxostat appropriate for hyperuricemia significantly ameliorated hypertension in SHR. On the other hand, a couple of studies showed that chronic treatment with allopurinol, a classic type of XO inhibitor, failed to lower blood pressure in SHRs (Trachtman et al. 1991; Laakso et al. 1998, 2004; Yamamoto et al. 2006). With respect to the possible mechanisms for the inconsistent results between the two XO inhibitors, a couple of possibilities are raised as follows. First, allopurinol does produce oxidative stress when metabolized to oxypurinol as described above (Galbusera et al. 2006), while febuxostat does not. Second, both allopurinol and oxypurinol showed the limitation to inhibit the endothelial-binding xanthine oxidase (Kelley et al. 2004; Malik et al. 2011). Third, allopurinol has been shown to be more nephrotoxic in SHR than in WKY, thereby masking its beneficial effect on hypertension (Trachtman et al. 1991). These may explain, at least in part, the difference in impact on hypertension of SHR between allopurinol and febuxostat.

XO inhibitors such as tungsten and allopurinol have been reported to improve endothelial dysfunction in several animal models and human diseases such as atherosclerosis and coronary heart disease (Schroder et al. 2006; Dopp et al. 2011; George et al. 2006; Yiginer et al. 2008). Our recent work demonstrated that febuxostat improved endothelial dysfunction also in high-fat diet-induced obese diabetic mice (Masuzaki et al., manuscript submitted). Based on our results in various experimental hypertension models, XO inhibitors may exert favorable effects in several types of endothelial dysfunction.
et al. 2013). Therefore, XO derived from damaged organs may contribute to the elevation of plasma and vascular XO activities in SHRs.

Our data demonstrated that endothelial relaxation by ACh was improved in febuxostat-treated SHRs compared with the vehicle-treated SHRs, while the response to SNP in aorta was unaltered. Enhanced ACh-induced relaxation in vascular endothelium by febuxostat is attributed, at least partly, to the increase in NO response, resulting from the scavenge of NO by ROS, which reacts rapidly with NO to form peroxynitrite (Trujillo et al. 1998). To assess the involvement of NO scavenge in this experimental paradigm, we measured vascular nitrotyrosine levels. Protein nitrosylation is a representative indicator of peroxynitrite formation in vascular tissues. As expected, SHRs showed significantly elevated nitrotyrosine levels in the aortic homogenate as compared to WKY rats, which were normalized by the treatment of febuxostat. Thus, the data suggest that febuxostat attenuates NO scavenge and subsequently increases the availability of NO. Furthermore, peroxynitrite per se induces endothelial and tissue injuries in various pathophysiological conditions (Pacher et al. 2002a, b, 2005; Szabo et al. 2002a, b, 2004; Ungvari et al. 2005). Hence, suppression of peroxynitrite by febuxostat is also beneficial to ameliorate endothelial dysfunction.

It is well documented that elevation of serum uric acid per se is a potent risk for dysfunction of kidney and vascular system, resulting in hypertension (Sundstrom et al. 2005; Galbusera et al. 2006; Krishnan et al. 2007; Grayson et al. 2011). In animal models, hyperuricemia in rats leads to increase in blood pressure, while the alleviation of hyperuricemia with urate-lowering drugs including benzbromarone leads to the reversal of hypertension (Mazzali et al. 2001; Nakagawa et al. 2003; Sanchez-Lozada et al. 2008a, b). In clinical settings, reduction of uric acid with allopurinol in hyperuricemic, hypertensive adolescents did ameliorate blood pressure profile (Feig et al. 2008). In contrast to these findings, the present study used SHRs and the control normotensive WKY rats and compared the results to minimize the possible influence of uric acid-dependent actions, because the serum uric acid level in SHRs is similar to WKY rats (Trachtman et al. 1991; Durante et al. 2010). Treatment of febuxostat equipotently lowers plasma uric acid levels in both WKY rats and SHRs and ameliorated hypertension in SHRs, suggesting that the BP-lowering effects of febuxostat are caused by the suppression of ROS production independent of the lowering effect on plasma uric acid. Comparison study using XO inhibitors and other hypouricemic agents such as benzbromarone would be required to test this hypothesis.

**Study limitations**

In the present study, the dose of febuxostat was limited to about 3 mg/kg/day, because the higher dose of febuxostat highly causes xanthine calculi as described (Isa et al. 1968). As a matter of fact, febuxostat at 3 mg/kg/day could not attain the complete inhibition of XO systemically in this study. Therefore, we could not assess the maximal
effects of febuxostat on the hypertension and endothelial
dysfunction in the current experimental setting. The pre-
sent study used SHR as a representative animal model of
hypertension and demonstrated the potential anti-
hypertensive effects by pharmacological XO inhibition.
Recently, Boban et al. reported that circulating xanthine
oxidase activity was increased in patients with essential
hypertension (Boban et al. 2014), which is consistent with
our results that plasma XO activity was considerably ele-
vated in SHR. Therefore, XO inhibitor may be beneficial
for the treatment of some forms of hypertension in humans.
However, there is little information about the relationship
between plasma XO activity and other forms of hyperten-
sion such as renal hypertension and pulmonary hyperten-
sion. In this context, further studies are warranted to clarify
the clinical implication of XO inhibition in various types of
diseases.

With respect to the prediction of clinical efficacy of XO
inhibition, we should be careful about extrapolating the results
in experimental animals to humans. Importantly, unlike
humans, almost all animals including rodents have uricase, a
urate oxidase enzyme. Although few animal species that mim-
ic uric acid metabolism in humans are known (Oda et al. 2002;
Bannasch et al. 2008), there seems no available model of
hypertension in these species. Therefore, clinical studies are
required to verify the effects of XO inhibition on the
hypertension and endothelial dysfunction in human
pathophysiology.

In conclusion, present study demonstrates that exaggerated
XO activity and resultant increase in oxidative stress in SHRs
contribute, at least partly, to their hypertension and endothelial
dysfunction. This notion was endorsed by the finding that
chronic treatment of selective XO inhibitor febuxostat
improves a line of vascular phenotypes. Our data suggest that
pharmacological inhibition of exaggerated XO may be
valuable not only for hyperuricemia but also for treating some
forms of hypertension and related endothelial dysfunction in humans.

Compliance with ethical standards

Funding This research was supported by Teijin Pharma Limited.

Conflict of interest Dr. Masuzaki declares no conflicts of interest.

Dr. Masuzaki is supported in part by Grants-in-Aid from the Ministry
of Education, Culture, Sports, Science and Technology of Japan (MEXT)
KAKENHI (Grant 24591338, 2012–2014) and by Special Account
Budget for Education and Research (2011–2015) granted by the Japan
Ministry of Education, Culture, Sports, Science and Technology of Japan.

Ethical approval All procedures performed in studies involving ani-
mal were in accordance with the ethical standards of the Teijin Institute
for Bio-Medical Research Institute, Teijin Pharma Limited, Tokyo, Japan.

Open Access This article is distributed under the terms of the Creative
Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.

References

Aslan M, Ryan TM, Adler B, Townes TM, Parks DA, Thompson JA,
Tousson A, Gladwin MT, Patel RP, Tarpey MM, Batinic-Haberle I,
White CR, Freeman BA (2001) Oxygen radical inhibition of nitric
oxide-dependent vascular function in sickle cell disease. Proc Natl
Acad Sci U S A 98:15215–15220. doi:10.1073/pnas.221292098

Augustin AJ, Boker T, Blumenroder SH, Lutz J, Spitznas M (1994) Free
radical scavenging and antioxidant activity of allopurinol and
oxyprinolin in experimental lens-induced uveitis. Invest
Ophthalmo Vis Sci 35:3897–3904

Bannasch D, Safa N, Young A, Karmi N, Schaible RS, Ling GV (2008)
Mutations in the SLC2A9 gene cause hyperuricosuria and hyperuri-
cemia in the dog. PLoS Genet 4:e1000246
Boban M, Kocic G, Radenkovic S, Pavlovic R, Cvetkovic T, Deljanin-Ilic M, Ilic S, Bobana MD, Djindjic B, Stojanovic D, Sokolovic D, Jevtovic-Stoimenov T (2014) Circulating purine compounds, uric acid, and xanthine oxidase/dehydrogenase relationship in essential hypertension and end stage renal disease. Ren Fail 36:613–618
Boon CM, Ng MH, Choo YM, Mok SL (2013) Super, red palm and palm oleins improve the blood pressure, heart size, aortic media thickness and lipid profile in spontaneously hypertensive rats. PLoS One 8, e55908. doi:10.1371/journal.pone.0055908
Boueiz A, Damarla M, Hassoun PM (2008) Xanthine oxidoreductase in respiratory and cardiovascular disorders. Am J Physiol Lung Cell Mol Physiol 294:L830–840. doi:10.1152/ajplung.0007.2008
Ceriello A (2008) Possible role of oxidative stress in the pathogenesis of hypertension. Diabetes Care 31(Suppl 2):S181–184. doi:10.2373/dc08-s245
Cutler JA, Sortlie PD, Wolz M, Thom T, Fields LE, Roccella EJ (2008) Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988–1994 and 1999–2004. Hypertension 52:818–827. doi:10.1161/01.HYP.108.113357
Dopp JM, Philippri NR, Marcus NJ, Olson EB, Bird CE, Moran JJ, Boueiz A, Damarla M, Hassoun PM (2008) Xanthine oxidoreductase in hypertension. Am J Hypertens 22:1333–1340
Dunne J, Frick K, Brosnan MJ, McIntyre M, Reid JL, Dominiczak AF, Hamilton KE, Brosnan MJ, Hassoun PM (2004) Binding of xanthine oxidase to glycosaminoglycans limits inhibition by oxypurinol. J Biol Chem 279:37231–37234. doi:10.1074/jbc.M402077200
Kerr S, Brosnan MJ, McIntyre M, Reid JL, Dominiczak AF, Hamilton CA (1999) Superoxide anion production is increased in a model of genetic hypertension: role of the endothelium. Hypertension 33:1353–1358
Krishnan E, Kwoh CK, Schumacher HR, Kuller L (2007) Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 49:298–303. doi:10.1161/01.HYP.0000254540.64564.b6
Laakso J, Mervaala E, Himberg JI, Teravainen TL, Karpanen H, Vapaatalo H, Lapatto R (1998) Increased kidney xanthine oxidoreductase activity in salt-induced experimental hypertension. Hypertension 32:902–906
Laakso JT, Teravainen TL, Martelin E, Vaskonen T, Lapatto R (2004) Renal xanthine oxidoreductase activity during development of hypertension in spontaneously hypertensive rats. J Hypertens 22:1333–1340
Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, Harrison DG (2003) Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 111:1201–1209. doi:10.1172/JCI14172
Li H, Horke S, Forstmann U (2013) Oxidative stress in vascular disease and its pharmacological prevention. Trends Pharmacol Sci 34:313–319
Liu W, Wang W, Song SW, Gu XF, Ma XJ, Su FY, Zhang H, Liu AJ, Su DF (2011) Synergism of telmisartan and amlodipine on blood pressure reduction and cardiorenal protection in hypertensive rats. J Cardiovasc Pharmacol 57:308–316. doi:10.1097/JFC.0b013e3182073e41
Lockette W, Otsuka Y, Carretero O (1986) The loss of endothelium-dependent vascular relaxation in hypertension. Hypertension 8:1161–66
Malik UZ, Hundle NJ, Romero G, Radi R, Freeman BA, Tarpey MM, Kelley EE (2011) Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production. Free Radic Biol Med 51:179–184. doi:10.1016/j.freeradbiomed.2011.04.004
Mazzali T, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ (2001) Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38:1110–1116
Morawietz H, Weber M, Kueckshchloss O, Lauer N, Hacker A, Kojda G (2001) Uregulation of vascular NAD(P)H oxidase subunit gp91phox and impairment of the nitric oxide signal transduction pathway in hypertension. Biochem Biophys Res Commun 285:1130–1135. doi:10.1006/bbrc.2001.5312
Nakagawa T, Mazzali M, Kang DH, Kojda G, Lan HY, Kivlighn S, Johnson RJ (2003) Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 23:2–7
Nickenig G, Harrison DG (2002) The AT(I)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation 105:393–396
Oda M, Satta Y, Takenaka O, Takahata N (2002) Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol 19:640–653
Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF (2003) An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem 278:1848–1855. doi:10.1074/jbc.M208307200
Ong SL, Vickers JJ, Zhang Y, McKenzie KU, Walsh CE, Whitworth JA (2007) Role of xanthine oxidase in dexamethasone-induced hypertension in rats. Clin Exp Pharmacol Physiol 34:517–519. doi:10.1111/j.1440-1681.2007.04605.x
Pacher P, Liaudet L, Mabley J, Komjati K, Szabo C (2002a) Pharmacologic inhibition of poly(adenosine diphosphate-ribose)
polymerase may represent a novel therapeutic approach in chronic heart failure. J Am Coll Cardiol 40:1006–1016

Pacher P, Mabley JG, Soriano FG, Liaudet L, Komjati K, Szabo C (2002b) Endothelial dysfunction in aging animals: the role of poly(ADP-ribose) polymerase activation. Br J Pharmacol 135:1347–1350. doi:10.1038/sj.bjp.0704627

Pacher P, Schulz R, Liaudet L, Szabo C (2005) Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmacol Sci 26:302–310. doi:10.1016/j.tips.2005.04.003

Radi R, Rubbo H, Bush K, Freeman BA (1997) Xanthine oxidase binding to glycosaminoglycans: kinetics and superoxide dismutase interactions of immobilized xanthine oxidase-heparin complexes. Arch Biochem Biophys 339:125–135. doi:10.1006/abbi.1996.9844

Sanchez-Lozada LG, Tapia E, Bautista-Garcia P, Soto V, Avila-Casado C, Vega-Campos IP, Nakagawa T, Zhao L, Franco M, Johnson RJ (2008a) Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Ren Physiol 294:F710–718. doi:10.1152/ajpregu.00454.2007

Sanchez-Lozada LG, Tapia E, Soto V, Avila-Casado C, Franco M, Zhao L, Johnson RJ (2008b) Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricemia. Nephrol, Dial, Transplant Off Publ Eur Dial Transplant Assoc Eur Ren Assoc 23:1179–1185. doi:10.1093/ndt/gfm783

Schröder K, Vecchione C, Jung O, Schreiber JG, Shiri-Sverdlov R, van Gorp PJ, Busse R, Brandes RP (2006) Xanthine oxidase inhibitor tungsten prevents the development of atherosclerosis in ApoE knockout mice fed a Western-type diet. Free Radic Biol Med 41:718. doi:10.1016/j.freeradbiomed.2006.05.001

Sundstrom J, Sullivan L, D’Agostino RB, Levy D, Kannel WB, Vasan RS (2005) Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 45:28–33. doi:10.1161/01.HYP.0000150784.92944.9a

Szabo C, Mabley JG, Moeller SM, Shimanovich R, Pacher P, Virag L, Soriano FG, Van Duzer JH, Williams W, Salzman AL, Groves JT (2002a) Part I: pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: studies with FP15, a novel potent peroxynitrite decomposition catalyst. Mol Med 8:571–580

Szabo C, Zanchi A, Komjati K, Pacher P, Krolewski AS, Quist WC, LoGerfo FW, Horton ES, Veves A (2002b) Poly(ADP-Ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity. Circulation 106:2680–2686

Tan S, McAdams M, Royall J, Freeman BA, Parks DA (1998) Endothelial injury from a circulating mediator following rat liver ischemia. Free Radic Biol Med 24:427–434

Tanito M, Nakamura H, Kwon YW, Teratani A, Masutani H, Shioji K, Kishimoto C, Oihara A, Horie Y, Yodoi J (2004) Enhanced oxidative stress and impaired thioredoxin expression in spontaneously hypertensive rats. Antioxid Redox Signal 6:89–97. doi:10.1089/152308604771978381

Tian N, Tharsher KD, Gundy PD, Hughson MD, Manning RD Jr (2005) Antioxidant treatment prevents renal damage and dysfunction and reduces arterial pressure in salt-sensitive hypertension. Hypertension 45:934–939. doi:10.1161/01.HYP.0000160404.08866.5a

Touyz RM (2004) Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension 44:248–252. doi:10.1161/01.HYP.0000138070.47616.9d

Trachtmann H, Valderrama E, Futterweit S (1991) Nephrotoxicity of allopurinol is enhanced in experimental hypertension. Hypertension 17:194–202

Trujillo M, Alvarez MN, Peluffo G, Freeman BA, Radi R (1998) Xanthine oxidase-mediated decomposition of S-nitrosothiols. J Biol Chem 273:7828–7834

Ungvari Z, Gupte SA, Recchia FA, Battasi S, Pacher P (2005) Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol 3:221–229

Viel EC, Benkirane K, Javeshghani D, Touyz RM, Schiffin EL (2008) Xanthine oxidase and mitochondria contribute to vascular superoxide anion generation in DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol 295:H281–288. doi:10.1152/ajpheart.00304.2008

Yamamoto Y, Ogino K, Iwaga G, Matsuura T, Kaetsu Y, Sugihara S, Matsuura K, Mieake J, Hamada T, Yoshiada A, Iwaga O, Yamamoto T, Shigemasa C, Hisatome I (2006) Allopurinol reduces neointimal hyperplasia in the carotid artery ligation model in spontaneously hypertensive rats. Hypertens Res Off J Jpn Soc Hypertens 29:915–921. doi:10.1291/hypres.29.915

Yigitner O, Ozcelik F, Inanc T, Aparci M, Ozmen N, Cingozbay BY, Kardesoglu E, Suleymanoglu S, Sener G, Cebeci BS (2008) Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome. Clin Res Cardiol Off J Ger Card Soc 97:334–340

Yokoyama Y, Beckman JS, Beckman TK, Wheat JK, Cash TG, Freeman BA, Parks DA (1990) Circulating xanthine oxidase: potential mediator of ischemic injury. Am J Physiol 258:H564–570

Zhang Y, Chan MM, Andrews MC, Mori TA, Croft KD, McKenzie KU, Schyvens CG, Whitworth JA (2005) Apoecinyn but not allopurinol prevents and reverses adrenocorticotropic hormone-induced hypertension in the rat. Am J Hypertens 18:910–916. doi:10.1016/j.amjhyper.2005.02.017

Zicha J, Kunes J (1999) Ontogenetic aspects of hypertension development: analysis in the rat. Physiol Rev 79:1227–1282